NRIX · Nurix Therapeutics, Inc.
Market Cap
$2.79B
Shares
103.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$26.88
Open$26.80
Day$26.24–27.50
52W close$8.24–27.79
Avg vol 30d1.1M
Short int18.0M · 17.3% float · 18.1d
Short vol54%
Last earningsJul 9, 2026
DataJul 2020–Aug 2026
Filing10-Q · Jul 9
Up next
Next earnings call
Jul 12, 2027
Est · unconfirmed
· in 45 wks
FQ3-26 quarter ends
~Aug 30, 2026
Est
filed Jul 9, 2026
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.5 · calm
Equity put/call 0.39
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+45%
above
Price vs 50-day avg
+12%
above
RSI (14)
62
neutral
MACD trend
Negative
52-week position
95%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+14%
trailing
6-month return
+78%
trailing
YTD return
+42%
this year
Relative strength
+63%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $24 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +47 funds added
Insider flow
Distributing
Net -$246.4K over 90 days · 100% sells
Short interest
Falling
17.33% of float · ▼ -2.0% MoM · 18.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
212 holders — near 3-yr high, broad support
Squeeze score
77
high risk · 0–100
Fundamentals
Revenue growth
+99%
Y/Y
EPS growth
−6%
Y/Y
Free cash flow
$-263.5M
Balance sheet
$247.0M
net cash
Quant / Vol
risk profile
Volatility
61%
annualized · 1-yr
Max drawdown
−33%
past year
ATR
3.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+45%
Bullish
Price vs 50-day avg
+12%
Bullish
RSI (14)
62
Neutral
MACD trend
Negative
Bearish
52-week position
95%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $24 › 200d $19 — 50d above 200d
Institutional flow
Accumulating
+8% holders QoQ · +47 funds added
Insider flow
Distributing
Net -$246.4K over 90 days · 100% sells
Short interest
Falling
17.33% of float · ▼ -2.0% MoM · 18.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
212 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $8
Now $27 · 95%
Range high $28
vs 200-day avg +45%
vs 50-day avg +12%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NRIX
this stock
Nurix Therapeutics, Inc.
|
$2.79B | +41.7% | +99.3% | — | 17.3% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.8% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.27B | +4.6% | +20.8% | 19.6 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +25.9% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NRIX | -0.7% | +14.0% | +78.0% | +15.8% | +41.7% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -1.8% | +10.0% | +63.3% | +12.6% | +28.6% |
Key facts
CIK
1549595
CUSIP
67080M103
13F (30d)
193 filings
187 filers
Visit website
Investor relations